Albany, NY -- (SBWIRE) -- 06/05/2020 -- Alzheimer's Disease Market Insights, Epidemiology and Market Forecast-2030
DelveInsight launched a new report on Alzheimer's Disease Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report
1. Alzheimer's Disease affects an estimated 6.08 million people in the United States.
2. Approximately 200,000 people younger than 65 years constitute the younger-onset population of Alzheimer's Disease in the US.
3. The females show a higher proportion of Alzheimer's Disease Prevalence as compared to males in the 7MM.
Key benefits of the report
1. Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer's Disease epidemiology and Alzheimer's Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alzheimer's Disease market report provides insights into the current and emerging therapies.
3. Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer's Disease market.
Request for sample pages
Alzheimer's disease attacks the cells of the brain and neurotransmitters, affecting the way brain functions, memory and behaviour. There is no known cure for the disease, and current approaches focus on helping people maintain mental function, manage behavioural symptoms, and slow down specific problems, such as memory loss. Two categories of drugs are approved for Alzheimer's disease treatment: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.
Cholinesterase inhibitors act by increasing the level of acetylcholine; a chemical used by nerve cells to communicate with each other and is vital for learning, memory, and cognitive functions. Of this category, three drugs: Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne) are FDA-approved for the treatment of Alzheimer's disease and are used to treat mild-to-moderate Alzheimer's (donepezil can be used for severe Alzheimer's as well). Donepezil can be used in all stages of Alzheimer disease. Galantamine and rivastigmine are approved for treatment in mild-to-moderate Alzheimer disease only. Donepezil and galantamine are rapid, reversible inhibitors of acetylcholinesterase. Rivastigmine is a slow, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. Most common side effects of cholinesterase inhibitors are gastrointestinal-like nausea, vomiting, and diarrhoea.
Partial N-Methyl D-aspartate (NMDA) antagonist includes memantine. Memantine (Namenda) is used to treat moderate-to-severe Alzheimer's disease. However, these drugs do not change the underlying disease process. They are useful for some but not all people and may help only for a limited time. The FDA has also approved Aricept and Namzaric, a combination of Namenda and Aricept, for the treatment of moderate-to-severe Alzheimer's disease. Dizziness, body aches, headache, and constipation are common side effects. It can be taken in combination with cholinesterase inhibitors.
The launch of the emerging therapies is expected to significantly impact Alzheimer's Disease treatment scenario in the upcoming years:-
Drugs covered
1. AGB101
2. Bryostatin-1
3. COR388 HCL
4. Eltoprazine
5. ALZT-OP1
6. Brexpiprazole
7. AKST/GRF6019
8. AXS-05
9. Tricaprilin
10. TRx0237
11. RO7105705
12. Azeliragon (TTP488)
And many others
The key players in Alzheimer's Disease market are:
1. AgeneBio
2. Neurotrope Bioscience
3. Cortexyme
4. Amarantus Bioscience Holdings
5. AZ Therapies
6. Otsuka Pharmaceutical
7. Alkahest
8. Axsome Therapeutics
9. Cerecin
10. TauRx Therapeutics
11. Genentech
12. vTv Therapeutics
And many others
Table of contents
1. Report Introduction
2. Alzheimer's Disease Market Overview at a Glance
3. Alzheimer's Disease Disease Background and Overview
4. Alzheimer's Disease Epidemiology and Patient Population
5. Epidemiology of Alzheimer's Disease by Countries (2017–2030)
5.1. United States- Epidemiology (2017–2030)
5.2. EU-5 - Epidemiology (2017–2030)
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Alzheimer's Disease Treatments & Medical Practices
7. Alzheimer's Disease Marketed Products
7.1. Aricept: Eisai
7.2. Exelon: LTS Lohmann Therapie-Systeme/Novartis
7.3. Oligomannate: Green Valley Pharmaceuticals
8. Alzheimer's Disease Emerging Therapies
8.1. Key Cross Competition
8.2. AGB101: AgeneBio
8.3. Bryostatin-1: Neurotrope Bioscience
8.4. COR388 HCL: Cortexyme
8.5. Eltoprazine: Amarantus Bioscience Holdings
8.6. ALZT-OP1: AZ Therapies
8.7. Brexpiprazole: Otsuka Pharmaceutical
8.8. AKST/GRF6019: Alkahest
8.9. AXS-05: Axsome Therapeutics
8.10. Tricaprilin: Cerecin
8.11. TRx0237: TauRx Therapeutics
8.12. RO7105705: Genentech
8.13. Azeliragon (TTP488): vTv Therapeutics
9. Alzheimer's Disease Market Size
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. Italy Market Size
10.5. Spain Market Size
10.6. United Kingdom Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
13. Alzheimer's Disease Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight